Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
430 JPY | 0.00% | +3.61% | -38.75% |
Mar. 19 | SanBio Eyes Approval for Brain Injury Treatment Drug SB623 By March | MT |
Mar. 19 | Jefferies Adjusts SanBio’s Price Target to 270 Yen From 310 Yen, Keeps at Underperform | MT |
Sales 2025 * | - | Sales 2026 * | 660M 4.29M | Capitalization | 29.51B 192M |
---|---|---|---|---|---|
Net income 2025 * | -3.3B -21.39M | Net income 2026 * | -3.53B -22.91M | EV / Sales 2025 * | - |
Net Debt 2025 * | 226M 1.47M | Net Debt 2026 * | 3.03B 19.7M | EV / Sales 2026 * | 49.3 x |
P/E ratio 2025 * |
-8.76
x | P/E ratio 2026 * |
-8.21
x | Employees | 29 |
Yield 2025 * |
-
| Yield 2026 * |
-
| Free-Float | 71.15% |
Latest transcript on SanBio Company Limited
1 week | +3.61% | ||
Current month | +3.61% | ||
1 month | +7.50% | ||
3 months | -31.96% | ||
6 months | -8.12% | ||
Current year | -38.75% |
Managers | Title | Age | Since |
---|---|---|---|
Keita Mori
CEO | Chief Executive Officer | 56 | 13-02-26 |
Shinya Hirata
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Noboru Kotani
BRD | Director/Board Member | 67 | 13-02-28 |
Keita Mori
CEO | Chief Executive Officer | 56 | 13-02-26 |
Toru Kawanishi
CHM | Chairman | 56 | 13-02-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 2 M€ | -.--% | ||
0.01% | 7 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - | |
0.00% | 773 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 430 | 0.00% | 119 900 |
24-05-02 | 430 | +2.38% | 475,100 |
24-05-01 | 420 | +1.20% | 376,100 |
Delayed Quote Japan Exchange, May 06, 2024 at 08:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.75% | 193M | |
+9.15% | 105B | |
-1.08% | 104B | |
+5.79% | 22.94B | |
-11.55% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.91% | 16.96B | |
+7.55% | 14.16B | |
+40.04% | 12.63B |
- Stock Market
- Equities
- 4592 Stock